Navigation Links
EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models

198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, produc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
(Date:6/19/2013)... 2013 DST Health Solutions, LLC (DSTHS), a ... plans, integrated delivery systems, and health care providers, has ... Service (MDMS) has jumped significantly. A ... pricing of medical prescription drug claims, MDMS ... medical drug claims processes. As specialty drug demand grows ...
(Date:6/19/2013)... , June 19, 2013   Life Technologies ... a licensing agreement granting Suzhou Ribo Life Sciences ... siRNA therapeutics in China ... formulate proprietary siRNA molecules in combination with Invivofectamine® ... address human diseases with high unmet medical need ...
(Date:6/19/2013)... 19, 2013  It may seem like an odd pairing: ... cancer. But these were two of the most talked about ... Annual Meeting & Expo that just convened in ... focus by some of the top internal medicine experts in ... new research that can not only save lives, but help ...
Breaking Medicine Technology:Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4
... Calif., Dec. 14, 2010 Samplify Systems, Inc., ... for the ultrasound market, is pleased to announce ... imaging has won Electronic Design Magazine,s ... medical category.  Details of Samplify,s AutoFocus™ beamforming technology ...
... VIVUS, Inc. (Nasdaq: VVUS ) today announced ... secure regulatory approval for QNEXA® in the U.S., submitted a ... to address items in the FDA,s Complete Response Letter (CRL), ... the Endocrine and Metabolic Division of the FDA has granted ...
Cached Medicine Technology:Samplify's AutoFocus™ Beamforming Technology Awarded Electronic Design's 'Best of 2010' 2VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 2VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA® 3
(Date:6/19/2013)... (June 19, 2013) The results of three important ... Neurosurgery , official journal of the Congress ... by Lippincott Williams & Wilkins , a part ... indicates that continuous "machine learning" using artificial neural networks ... patients with advanced brain cancers. Another study in the ...
(Date:6/19/2013)... disparities between minority and white clients in success ... these disparities vary widely from state to state. ... states there,s something amiss," says Stephan Arndt, Ph.D., ... strong racial and ethnic disparities for people in ... successfully, and those disparities are something we need ...
(Date:6/19/2013)... Casual, no-strings sexual encounters are increasingly common ... likely than others to "hook up"? A new ... for Behavioral and Preventive Medicine, published online by ... there are certain factors and behaviors associated with ... , "Given the potential for negative emotional and ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Effective Environmental Services ... of new websites. These online links are devoted to a ... Tank cleaner, Organic Odor Control Mold Magician and others. , ... fish and animals in the water as well as living ... sludge buildup that can accumulate at the bottom of a ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 North ... announced organizational changes to advance development of its ... said, “To support the advanced development of our ... changes to the Company’s management structure and engaged ... The Company announced that Michael Galiger will serve ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Why are some college students more likely to 'hook up'? 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3
... September 10 IDenta Corp. (OTC:,IDTA.PK) announced today ... a recent French television news broadcast. TF1, the ... 7, 2007 during an evening,news program (at 8 ... Police,using the IDenta cocaine detection kit to test ...
... N.Y., Sept. 10 Physicians and patients,of ... benefit from an,enhanced partnership between Physicians Practice ... more than 7,000 physicians in Brooklyn,and Staten ... thereby,improving patient care. (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/NETU093LOGO ...
... Sept. 10 Mylan Laboratories Inc.,(NYSE: MYL ... received,tentative approval from the U.S. Food and Drug ... for Topiramate Capsules, 15 mg and,25 mg. ... McNeil,Pharmaceuticals, Topamax(R) Sprinkle Capsules which had U.S. sales ...
... Sept. 10 Marianjoy Medical,Group is pleased to ... medicine and rehabilitation practice which is based in,Wheaton, ... of Rush Oak Park Hospital,s,Rehabilitation Program and Services. ... medicine, and his medical practice addresses the,medically complex ...
... 10 Maxim Health Systems today,announced it will launch ... Maxim will provide flu shots nationwide through more,than 24,000 ... helps users find a convenient location for,vaccination clinics ... the site to,obtain times and locations for clinics. ...
... N.J., Sept. 10 Companies spend huge sums on,consultants ... and,profitable. But too often, advertising and marketing is left ... that requested an unbiased second opinion,for their advertising and ... and marketing consultancy. Why is advertising neglected? Anthony ...
Cached Medicine News:Health News:Drug Detection Kits Manufactured By IDenta Corp. Shown During French Television Broadcast (at TF1) - Product Aids French Police In Bust of 600 Kilograms Of Cocaine 2Health News:Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors 2Health News:Dr. Mahesh Ramachandran Joins Marianjoy Medical Group 2Health News:Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide 2Health News:Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide 3Health News:CEOs Need an Advertising Check Up or Second Opinion 2
... Compact Sigma is designed to easily ... precise mechanical coupling eliminates clumsy time ... performed as well. Dorniers patented isocentric ... ,Positioning is simple using the Dornier ...
Used for temporary control of male urinary incontinence due to surgery or neurogenic disorder. Supplied non-sterile. Reusable. Intended for single patient use only....
... ideally suited for high volume stone centers. This ... and an advanced urological table. With the Dornier ... provides successful treatments for a full range of ... URS and PCN procedures are easy. One of ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
Medicine Products: